Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab

NCT00740415 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT00740415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00740415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
August 31, 2015
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma